Printer Friendly

Galapagos reports positive Phase I data with GLPG1205 in inflammatory disorders.

(SeeNews) - Dec 4, 2013 -A Belgian biotechnology firmA GalapagosA (EBR:GLPG) said today GLPG1205,A a first-in-class molecule for inflammatory disorders, had shownA good safety profileA and favourable drug properties in a Phase I clinical study.

The study's goal was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single and multiple ascending doses of GLPG1205, which is being developed togetherA with Janssen Pharmaceutica. The trial enrolled 40 healthy volunteers at a clinical centre in Belgium.

The positive data encourages GalapagosA to initiate a Phase IIa study withA GLPG1205 in patients withA a chronic inflammatory bowel condition.

GLPG1205 is the first molecule that is clinically tested against this target, chief scientific officer (CSO)A Piet Wigerinck said, expressing his satisfaction with the study's outcome.A
COPYRIGHT 2013 AII Data Processing Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:SeeNews Belgium
Geographic Code:3ECUD
Date:Dec 4, 2013
Previous Article:Belgium's 11-mo bankruptcy number hits 2012 record.
Next Article:Umicore JV opens automotive catalyst centre in Japan.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters